Kayla Cooley
Family · Wiggins, MSNPI 1003404732
Payments from drug & device makers
Across 128 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$283
- AstraZeneca$265
- Novo Nordisk$247
- Lilly USA, LLC$216
- Merck$167
- Astellas Pharma US Inc$144
- plus $870 from 14 others
What the payments were for
- Food & beverage$2,11797%
- Education$753%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 22 | $283 |
| AstraZeneca | 15 | $265 |
| Novo Nordisk | 15 | $247 |
| Lilly USA, LLC | 13 | $216 |
| Merck | 8 | $167 |
| Astellas Pharma US Inc | 5 | $144 |
| AbbVie | 8 | $143 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $129 |
| Vanda Pharmaceuticals Inc. | 6 | $105 |
| Pfizer | 5 | $79 |
| Amgen | 5 | $76 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Abbott | 2 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $46 |
| Novartis | 2 | $42 |
| Bayer | 3 | $41 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Mylan Specialty L.p. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$2,192 in reported general payments places this provider in the 80th percentile of 3,007 family providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 48 | $41,756 |
| FarxigaDapagliflozin Propanediol | 31 | $24,519 |
| OzempicSemaglutide | 20 | $21,747 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $17,532 |
| JanuviaSitagliptin Phosphate | 11 | $17,405 |
| LinzessLinaclotide | 11 | $5,988 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $2,665 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,760 |
| Pregabalin | 22 | $950 |
| Fluticasone Propionate | 66 | $752 |
| Atorvastatin Calcium | 86 | $732 |
| Doxycycline Hyclate | 67 | $605 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 12 | $574 |
| Gabapentin | 48 | $498 |
| Rosuvastatin Calcium | 32 | $443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $265 | $24,51931 claims |
| Novo NordiskOzempic | $247 | $21,74720 claims |
| GSKTrelegy Ellipta | $283 | $17,53228 claims |
| MerckJanuvia | $167 | $17,40511 claims |
| AbbVieLinzess | $143 | $5,98811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,007 family providers in Mississippi.
Other family in Wiggins
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.